Neyer is changing its name and rethinking its future. The design-build firm will now be called Merus − a combination of the words "merit" and "us" – and an ode to the fact that the company has ...

Merus shares rise after the FDA grants Breakthrough Therapy designation for petosemtamab in combination with pembrolizumab for head. Investor optimism grows as the designation accelerates ...

Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 bispecific, petosemtamab, as “significantly de-risked ...

Dutch biopharma Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer. Bizengri (zenocutuzumab) targets the ...

Merus (NASDAQ:MRUS – Get Free Report) saw a large drop in short interest in the month of February.As of February 15th, there was short interest totalling 6,640,000 shares, a drop of 13.5% from ...

Merus Shares Are Up Today: What's Going On? Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted ...

Merus has a 12 month low of $37.77 and a 12 month high of $61.61. The firm has a market capitalization of $2.75 billion, a PE ratio of -10.18 and a beta of 1.11. Hedge Funds Weigh In On Merus ...

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $93.00. The company’s shares closed yesterday at $46.22.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative ...